Clinical Question: Is meloxicam as ...

Clinical Question: Is meloxicam as safe as other nonsteroidal anti-inflammatory physics (NSAIDs)?

Setting: Various (meta-analysis)

research Design: Meta-analysis (randomized controlled trials)

Synopsis: Meloxicam is an NSAID that preferentially inhibits the cyclooxygenase-2 receptor. Investigators collection of standing watered data from 28 published and unpublished trials that included a total of 24196 patients to assess the safety profile of meloxicam. The duration of greatest in number trials was 60 days or les Meloxicam in a dosage of 75 mg or 15 mg for day (n = 13,118) was compared with diclofenac in a dosage of 100 to 150 mg by means of day (n = 5,464), piroxicam in a dosage of 20 mg through day (n = 5,371), or naproxen in a dosage of 500 mg twice by means of day (n = 243).

Serious gastrointestinal (GI) complications included gastric or duodenal perforation, gastric exit obstruction, and hemodynamically important GI bleeding. Thromboembolic marked occurrences included myocardial infarction and calamity but not deep venous thrombosis or pulmonary embolism. The investigators who judg whether adverse affairs met the definitions used in this application of mind were blinded to treatment allocation.

Fifty-four serious GI issues occurred in less than 1 percent of any treatment assign places to meaning that all numbers needinessed to treat to harm (NNH) would be more than 100 Significantly fewer GI terminations occurred in patients receiving the 75-mg dosage of meloxicam compared with each of the other NSAIDs. At the 15-mg dosage, the risk with meloxicam was significantly les than the risk with piroxicam and nothing else Thromboembolic events were less every-day with either dosage of meloxicam than with diclofenac (NNH = 720; 95 percent confidence interval, 320 to 5717) There were no differences in the risk of cardiovascular circumstances occurring with meloxicam compared with piroxicam or naproxen, with inclinations favoring meloxicam.

Bottom Line: Short-term meloxicam at the 75-mg daily dosage is les likely than piroxicam, diclofenac, or naproxen to be associated with serious GI complications. However, the absolute risk differences are les than 1 percent Meloxicam has not been shown to be associated with heart attacks and visitations A direct comparison with ibuprofen is distressed (Level of Evidence: 1a)

investigation Reference: Singh G, et al. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am J M July 15 2004;117:100-6

Used with permission from French L Meloxicam as safe as a other NSAIDs. Accessed online January 25 2005 at: http://www.InfoPOEMs.com.

COPYRIGHT 2005 American Academy of Family Physicians

COPYRIGHT 2005 Gale Group